Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy

Journal of Clinical Oncology

Volumn 33, Issue 6, 2015, Pages 582-587

  Srikanthan, Amirrtha ^a   Tran, Ben ^a,d   Beausoleil, Michel ^b   Jewett, Michael A S ^a   Hamilton, Robert J ^a   Sturgeon, Jeremy F G ^c   O'Malley, Martin ^a   Anson Cartwright, Lynn ^a   Chung, Peter W M ^a   Warde, Padraig R ^a   Winquist, Eric ^b   Moore, Malcolm J ^a   Amir, Eitan ^a   Bedard, Philippe L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AREA UNDER THE CURVE; AREA UNDER THE RECEIVER OPERATING CHARACTERISTIC CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; GERM CELL TUMOR; HOSPITALIZATION; HUMAN; INTERMEDIATE RISK PATIENT; KHORANA SCORE; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROPERITONEAL LYMPH NODE METASTASIS; RETROPERITONEAL LYMPHADENOPATHY; RISK FACTOR; SCORING SYSTEM; VENOUS STASIS; VENOUS THROMBOEMBOLISM; BIOLOGICAL MODEL; BLOOD; CHEMICALLY INDUCED; COHORT ANALYSIS; LYMPHATIC SYSTEM DISEASE; NEOPLASMS, GERM CELL AND EMBRYONAL; PATHOLOGY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COHORT STUDIES; HUMANS; LYMPHATIC DISEASES; MODELS, BIOLOGICAL; NEOPLASMS, GERM CELL AND EMBRYONAL; VENOUS THROMBOEMBOLISM;

EID: 84923169029     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.6537     Document Type: Article

References (33)

1. Khorana AA: Malignancy, thrombosis and Trousseau: The case for an eponym. J Thromb Haemost 1:2463-2465, 2003
2. Blom JW, Doggen CJ, Osanto S, et al: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715-722, 2005
3. Khorana AA, Francis CW, Culakova E, et al: Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110:2339-2346, 2007
4. Seng S, Liu Z, Chiu SK, et al: Risk of venous thromboembolism in patients with cancer treated with Cisplatin: A systematic review and meta-analysis. J Clin Oncol 30:4416-4426, 2012
5. Prandoni P, Lensing AW, Piccioli A, et al: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484-3488, 2002
6. Lyman GH, Eckert L, Wang Y, et al: Venous thromboembolism risk in patients with cancer receiving chemotherapy: A real-world analysis. Oncologist 18:1321-1329, 2013
7. Elting LS, Escalante CP, Cooksley C, et al: Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 164: 1653-1661, 2004
8. Bredael JJ, Vugrin D, Whitmore WF Jr: Autopsy findings in 154 patients with germ cell tumors of the testis. Cancer 50:548-551, 1982
9. Lyman GH, Khorana AA, Kuderer NM, et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2189-2204, 2013
10. Khorana AA, Kuderer NM, Culakova E, et al: Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902-4907, 2008
11. Leizorovicz A, Cohen AT, Turpie AG, et al: Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110:874-879, 2004
12. Cohen AT, Davidson BL, Gallus AS, et al: Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. BMJ 332:325-329, 2006
13. Rajkumar SV, Jacobus S, Callander NS, et al: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 11:29-37, 2010
14. Weber DM, Chen C, Niesvizky R, et al: Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133-2142, 2007
15. Piketty AC, Fléchon A, Laplanche A, et al: The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer 93:909-914, 2005
16. Vlassov VV, Laktionov PP, Rykova EY: Circulating nucleic acids as a potential source for cancer biomarkers. Curr Mol Med 10:142-165, 2010
17. National Comprehensive Cancer Network: Testicular Cancer: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) (version 1.2014). Fort Washington, PA, National Comprehensive Cancer Network, 2014
18. Chew HK, Wun T, Harvey D, et al: Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458-464, 2006
19. Wattanakit K, Cushman M, Stehman-Breen C, et al: Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 19: 135-140, 2008
20. International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997
21. Moore RA, Adel N, Riedel E, et al: High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: A large retrospective analysis. J Clin Oncol 29:3466-3473, 2011
22. Weijl NI, Rutten MF, Zwinderman AH, et al: Thromboembolic events during chemotherapy for germ cell cancer: A cohort study and review of the literature. J Clin Oncol 18:2169-2178, 2000
23. Samama MM, Cohen AT, Darmon JY, et al: A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341: 793-800, 1999
24. Agnelli G, Gussoni G, Bianchini C, et al: Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study. Lancet Oncol 10:943-949, 2009
25. Palumbo A, Cavo M, Bringhen S, et al: Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial. J Clin Oncol 29:986-993, 2011
26. Agnelli G, George DJ, Kakkar AK, et al: Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366:601-609, 2012
27. Einhorn LH, Donohue J: Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293-298, 1977
28. Motzer RJ, Bosl GJ: Hemorrhage: A complication of metastatic testicular choriocarcinoma. Urology 30:119-122, 1987
29. Sweetenham JW, Whitehouse JM, Williams CJ, et al: Involvement of the gastrointestinal tract by metastases from germ cell tumors of the testis. Cancer 61:2566-2570, 1988
30. Chait MM, Kurtz RC, Hajdu SI: Gastrointestinal tract metastasis in patients with germ-cell tumor of the testis. Am J Dig Dis 23:925-928, 1978
31. Beyer J, Albers P, Altena R, et al: Maintaining success, reducing treatment burden, focusing on survivorship: Highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24:878-888, 2013
32. Oldenburg J, Fosså S, Nuver J, et al: Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi125-vi132, 2013 (suppl 6)
33. Motzer RJ, Agarwal N, Beard C, et al: Testicular cancer. J Natl Compr Canc Netw 10:502-535, 2012